Press Release: Renova Therapeutics : Renova Therapeutics Announces Issuance of Patent Covering Delivery and Expression of Paracrine Genes

Renova™ Therapeutics, a biotechnology company developing gene and peptide-based treatments for cardiovascular and metabolic diseases, announced today that the European Patent Office has issued Patent No. 2814513, "Systemic Delivery and Regulated Expression of Paracrine Genes for Cardiovascular Diseases and Other Conditions" to The Regents of the University of California. Renova Therapeutics holds a worldwide exclusive license to this intellectual property. This patent protects the use of vectors containing paracrine genes for delivery of gene therapy for cardiovascular diseases. In addition, a patent has been granted by the Russian Patent office (Patent No. 2642605) directed to broad methods of gene therapy using paracrine genes for treatment of cardiovascular diseases and diabetes. Both of these patents will expire in February, 2033.